Search results

This study aims to assess the potency and dose of Δ-9-Tetrahidrocannabinol (THC) and Cannabidiol (CBD) in cannabis joints. This will enable better estimates of the degree of exposure in a user and contribute towards a better understanding of potential harmful effects.

Analysis of intact joints confiscated by law enforcement on the street in the autonomous region of Castilla y León (Spain) during the years 2017–2019.

This study analysed THC, CBN and CBD in marijuana joints (N = 744). Joints contain cannabis and tobacco (N = 729), had a median net weight 0.69 g (IQR = 0.28); concentration THC median was 6.30%(IQR = 4.51) and THC median dose 42 mg (IQR = 32.75). A total of 35.5% mixed joints contained CBN – median percentage 0.61% (IQR = 0.51). CBD was detected 10.3% of mixed joints – median percentage 0.13% (IQR = 0.12) and median dose 1 mg (IQR = 0.92). CBD/THC ratio presented median value of 0.02 (IQR = 0.02). The samples analysed comprised pure cannabis joints (N = 15), with THC median 11.86% (IWR = 6.30) or median dose of 118 mg.

The study found high values for concentration and dose of THC and CBD in cannabis joints, warning of high exposures for the user and associated potential consequences. The results obtained contribute new perspectives on the definition of a standard cannabis unit.

The Canadian government legalized cannabis in 2018 and funded harm reduction campaigns to educate youth about the risks. Cannabis can contribute to psychosis in vulnerable populations, and consumption is common among youth in Early Psychosis Intervention (EPI) programs. The purpose of this study is to understand the views of youth in EPI programs on the risks related to cannabis and methods to reduce those risks.

A qualitative design and thematic analysis were used to understand the perspectives of youth in EPI programs (n = 15) towards cannabis risks and harm reduction.

Participants associated Δ−9 tetrahydrocannabinol (THC) with problems related to cognition, psychosis, respiration, addiction, motivation, finances, relationships and anxiety. Cannabidiol (CBD) was believed to be safe and risk-free. To reduce the risks associated with THC, participants suggested using in moderation, delaying use, using CBD over THC, accessing legal sources, avoiding high THC dosages and using non-combustible methods.

Participants self-selected to participate, were psychiatrically stable and may not represent youth in EPI programs with more severe psychotic symptoms.

Assessing risk perceptions, motives for use and perspectives towards the cannabis and psychosis connection can reveal educational needs. CBD may offer a harm reduction option for EPI clients wanting to decrease THC intake, though more research is needed and adverse effects should be explained. Educational campaigns should disseminate the connection between cannabis and psychosis to facilitate early intervention.

This study adds to the literature by highlighting knowledge of harm reduction methods and gaps in risk awareness among EPI program youth.

Hemp-based food products and supplements have gained popularity within recent years in Europe. Apart from the non-psychoactive cannabinoid, cannabidiol, these products may also contain Δ⁹-tetrahydrocannabinol (THC) which can be of concern for safety and regulatory compliance. In the European Union, the currently accepted limit for THC in hemp is 0.3%. As many hemp-based products have been withdrawn from the German market within recent months/years, this study aims to investigate the current safety limit and potential concerns based on available analytical data.

Therefore, a publicly accessible, analytical data set from the German food authority was analysed and complemented by literature data and expert opinions regarding THC in food products. Furthermore, critical exposures have been calculated based on different product types and limits.

A safety-based limit of 11.9 µg/kg/day is proposed. Importantly, the authors’ examination of hemp seed oils, one of the most common food products, showed that 4 of the 102 samples were identified as having a low-to-moderate risk for inducing impairment – confirming the general need for regulation. For hemp leaf tea and common supplements, calculated exposures to THC were not considered critical. This has been also reflected by the absence of intoxication reports in the scientific literature.

Whilst for most hemp-derived foods safety concerns for the general public are considered low, this may not be the case for some products, suggesting the general need for regulatory compliance. Nevertheless, a more realistic safety limit should be applied.

“Cannabis” and “cannabis resin” are derived from the Cannabis plant, used as herbal medications, in traditional medicine and as active pharmaceutical ingredients. Since 1961, they have been listed in Schedule IV, the most restrictive category of the single convention on narcotic drugs. The process to scientifically review and reschedule them was launched by the World Health Organisation (WHO) on 2 December 2016; it survived a number of hindrances until finally being submitted to a delayed and sui generis vote by the UN Commission on Narcotic Drugs on 2 December 2020, withdrawing “cannabis” and “cannabis resin” from Schedule IV.

To evaluate WHO’s scheduling recommendations, the process leading to the Commission vote and subsequent implications at global, national and patient/clinician levels. Narrative account of the four-year proceedings; review of the practical implications of both rejected and accepted recommendations.

The process was historically unprecedented, of political relevance to both medical Cannabis and evidence-based scheduling generally. Procedural barriers hampered the appropriate involvement of civil society stakeholders. The landscape resulting from accepted and rejected recommendations allow countries to continue creating decentralised, non-uniform systems for access to and availability of “cannabis” and “cannabis resin” for medical purposes.

Perspective of accredited observers; highlight of institutional issues and the lay of the land; contrast of stakeholders’ interpretations and engagement.

This paper aims to investigate the attraction of cannabis-infused soft drinks beverages among young Canadian consumers in the wake of a rise in multimodal cannabis consumption. It is an area of accelerated growth potential, with little research data currently available, and findings would inform stakeholders in the soft drinks market. The research participants were all university students in Ontario province, Canada.

Random convenience sampling data collection techniques were used to gather data from the Ontario-based participants. Reliability, factors loading and multiple regression analysis were administered to understand the impact of factors towards positive attitude.

The results reveal that price, impulsive personality, social insecurity and social norms all have a positive influence towards positive attitude. However, energy, taste and past experience failed to show any relationship with positive attitude. The results suggest that the individual consumer’s personality and social context have greater influence than price, a useful insight into the market trends for stakeholders within the industry.

The use of convenience sampling, due to the potentially sensitivity nature of the area of study, hinders the use of a sampling frame.

To the best of the authors’ knowledge, this study is the first of its kind to examine positive attitude with respect to cannabis-infused soft drinks among young consumers in Canada. It is of particular interest to stakeholders in the production and marketing sectors of the global beverage industry, and its findings will help inform this fledgling wing of that industry on how to move forward through the unknown territory with regard to consumer motivations.

This chapter looks at the past, present and future of international cannabis control required by the UN drug control conventions in the post-2016 United Nations General Assembly Special Session era with an eye on the next High Level Ministerial Segment (HLMS) at the UN Commission on Narcotic Drugs in 2019, and beyond. From a policy analysis perspective, the author meanders through the increasing tendency to legally regulate recreational cannabis markets notwithstanding the obligation enshrined in the UN drug control conventions to limit cannabis exclusively for ‘medical and scientific’ purposes. Taking into account relevant national and international developments, the chapter describes how the growing discomfort with the status of cannabis and the prohibitive and punitive approach stemming from the international drug control regime went through a process from soft to hard defections of the treaty obligations. The case of the Netherlands demonstrates the difficulty faced by reform-minded states in reconciling their wish for a different cannabis control mechanism with their obligations under international law, resulting in an incomplete regulation of its coffee-shop system, where small amounts of cannabis are tolerated for sale, but where the illicit supply to the shops remained unregulated. Subsequent more wide-ranging reforms to regulate cannabis from seed to sale in Uruguay, several US States and – in 2018 – in Canada, are clearly violating the obligations of the UN drug control conventions. Nevertheless, the HLMS will likely leave the elephant in the room untouched. The emerging paradigm shift regarding cannabis shows that a modernisation of the UN drug control regime is long overdue. This chapter discusses some of the options available.